β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: Implication of ethnicity

Molecular Medicine Reports

Volumn 7, Issue 1, 2013, Pages 259-265

  Pereira, Sabrina Bernardez ^a,b   Velloso, MÔNica Wanderley MonÇOres ^a   Chermont, Sérgio ^a   QuintÃO, Mônica Maria Pena ^a   Abdhala, Rosemery Nunes ^a   Giro, Camila ^a   Alves, Thiago Oliveira E ^a   Camacho, Viviane ^a   Contarato, Luiza De Fátima Maia ^a   Pena, Felipe Montes ^a   Balieiro, Henrique Miller ^a   Garcia, Maria Luiza Rosa ^a   Da Nóbrega, Antônio ClÁudio Lucas ^a   Ribeiro, Georgina Severo ^a   Mesquita, Evandro Tinoco ^a  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Ethnicity; Heart failure; Polymorphisms; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CREATININE; HEMOGLOBIN; SODIUM; URIC ACID;

ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; BODY MASS; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DNA ISOLATION; DNA POLYMORPHISM; DRUG RESPONSE; ECHOCARDIOGRAPHY; ETHNIC DIFFERENCE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PHENOTYPE; PHYSICAL EXAMINATION; PROGNOSIS; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SODIUM BLOOD LEVEL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 84873382286     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1120     Document Type: Article

References (30)

1. El Armouche A and Eschenhagen T: β-Adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 14: 225-241, 2009.
2. Cohn, JN, Levine TB and Olivari MT: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
3. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G and Butler J: The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54: 1747-1762, 2009.
4. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al: A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and betablocker response in human heart failure. Proc Natl Acad Sci USA 103: 11288-11293, 2006.
5. McNamara DM: Emerging role of pharmacogenomics in heart failure. Curr Opin Cardiol 23: 261-268, 2008.
6. Lang RM, Bierig M, Devereux RB, et al: Recommendations of chamber quantification. Eur J Echocardiogr 7: 79-108, 2006.
7. De Groote P, Lamblin N, Helbecque N, et al: The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 7: 966-973, 2005.
8. Maqbool A, Hall A, Ball S and Balmforth AJ: Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet 353: 897, 1999.
9. Xie HG, Dishy V, Sofowora G, et al: Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 11: 191-197, 2001.
10. Moore JD, Mason DA, Green SA, Hsu J and Liggett SB: Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A-G and c1165G-C. Hum Mutat 14: 271, 1999.
11. Small KM, McGraw DW and Liggett SB: Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43: 381-411, 2003.
12. Small KM, Wagoner LE, Levin AM, Kardia SL and Liggett SB: Synergistic polymorphisms of β1-and α2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135-1142, 2002.
13. Tesson F, Charron P, Peuchmaurd M, et al: Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. Cardigene Group. J Mol Cell Cardiol 31: 1025-1032, 1999.
14. Börjesson M, Magnusson Y, Hjalmarson A and Andersson B: A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21: 1853-1858, 2000.
15. Podlowski S, Wenzel K, Luther HP, et al: Beta1-adrenoceptor gen variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 78: 87-93, 2000.
16. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC and Walsh RA: The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102: 1534-1539, 1998.
17. Forleo C, Resta N, Sorrentino S, et al: Association of β-adrenergic receptor polymorphisms and progression of heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117: 451-458, 2004.
18. Moraga F, Troncoso R, Mellado R, et al: Interactions between beta1 and beta2 adrenergic receptor polymorphisms as risk factors for chronic heart failure. Rev Med Chil 136: 1371-1380, 2008 (In Spanish).
19. Bray MS, Krushkal J, Li L, et al: Positional genomic analysis identifies the beta(2)-adrenergic receptor gen as a susceptibility locus for human hypertension. Circulation 101: 2877-2882, 2000.
20. Terra SG, Hamilton KK, Pauly DF, et al: β1-Adenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet Genomics 15: 227-234, 2005.
21. White HL, de Boer RA, Maqbool A, et al: An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5: 463-468, 2003.
22. Magnusson Y, Levin MC, Eggertsen R, Nyström E, Mobini R, Schaufelberger M and Andersson B: Ser49Gly of β1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78: 221-231, 2005.
23. Latado AL, Lopes MB, Passos LC and Lopes AA: Does any evidence exist to treat heart failure based on race or ethnicity? Rev Assoc Med Bras 55: 110-116, 2009 (In Portuguese).
24. McNamara DM, Tam W, Sabolisnski ML, et al: Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail 15: 191-198, 2009.
25. Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659-1667, 2001.
26. Cohn JN, Fowler MB, Bristow MR, et al: Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 3: 173-179, 1997.
27. Packer M, Fowler MB, Roecker EB, et al: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106: 2194-2199, 2002.
28. Yancy CW, Laskar S and Eichhorn E: The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure. Congest Heart Fail 10: 34-37, 2004.
29. López-Sendón J, Swedberg K, McMurray J, et al: Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25: 1341-1362, 2004.
30. Wood AJ: Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med 344: 1394-1396, 2001.